MARSHALL WACE, LLP

Position in ALKS — Alkermes plc.

CIK 1318757 LONDON, X0

Position in ALKS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$35,336,024

+$31,701,451 QoQ

Shares Held

999,322

+669.3% QoQ

Ownership

0.600%

of shares outstanding

% of Portfolio

0.05%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

10 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $558,161,566 across 33 Drug Manufacturers - Specialty & Generic names. ALKS ranks #6 (6.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VTRS	Viatris Inc	9,349,817	$126,316,026
2	NBIX	Neurocrine Biosciences Inc	508,977	$67,052,628
3	LNTH	Lantheus Holdings, Inc.	611,747	$46,401,008
4	UTHR	UNITED THERAPEUTICS Corp	75,977	$45,052,841
5	RDY	Dr Reddys Laboratories Ltd	2,664,306	$36,900,638
6	ALKS	Alkermes plc. This page	999,322	$35,336,024
7	ELAN	Elanco Animal Health Inc	1,382,412	$33,081,118
8	COLL	Collegium Pharmaceutical, Inc	748,812	$24,763,212

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$35,336,024	999,322	+669.3%	Shares	Other	2026-05-15
2025-12-31	$3,634,573	129,899	-37.4%	Shares	Other	2026-02-13
2025-06-30	$5,936,889	207,511	-88.3%	Shares	Other	2025-08-13
2023-09-30	$49,522,071	1,768,014	+143.8%	Shares	Other	2023-11-14
2023-06-30	$22,694,910	725,077	+539.4%	Shares	Other	2023-08-14
2023-03-31	$3,196,858	113,404	0.0%	Shares	Other	2023-05-15
2022-12-31	$2,963,246	113,404	+438.9%	Shares	Other	2023-02-14
2021-09-30	$648,966	21,043	-56.1%	Shares	Sole	2021-11-15
2020-12-31	$955,425	47,891	+151.2%	Shares	Sole	2021-02-16
2020-03-31	$274,888	19,063	—	Shares	Sole	2020-05-15
No filing history on record for this holder in this stock.